NNZ-2566: A Gly–Pro–Glu analogue with neuroprotective efficacy in a rat model of acute focal stroke
@article{Bickerdike2009NNZ2566AG, title={NNZ-2566: A Gly–Pro–Glu analogue with neuroprotective efficacy in a rat model of acute focal stroke}, author={Michael J. Bickerdike and Gregory B. Thomas and David C Batchelor and Ernest S. Sirimanne and Wing Leong and Hai Lin and Frank Sieg and Ji-Yue Wen and Margaret A. Brimble and Paul W. R. Harris and Peter D. Gluckman}, journal={Journal of the Neurological Sciences}, year={2009}, volume={278}, pages={85-90} }
29 Citations
GPE and GPE analogues as promising neuroprotective agents.
- Biology, ChemistryMini reviews in medicinal chemistry
- 2012
This review will focus on structural modifications performed on the GPE molecule in order to obtain bioactive analogues with increased pharmacokinetic profile useful for the treatment of central nervous system injures and neurodegenerative disorders.
The role for IGF-1-derived small neuropeptides as a therapeutic target for neurological disorders
- Biology, MedicineExpert opinion on therapeutic targets
- 2015
These small neuropeptides provide effective neuroprotection by offering an improved pharmacokinetic profile and more practical route of administration compared with IGF-1 administration.
NNZ-2566, a Glypromate Analog, Attenuates Brain Ischemia-Induced Non-Convulsive Seizures in Rats
- Biology, MedicineJournal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism
- 2009
Results indicate that NNZ-2566 possesses a unique therapeutic potential as a safe prophylactic agent that synergistically provides neuroprotection and reduces injury-induced seizures.
IGF‐1 derived small neuropeptides and analogues: a novel strategy for the development of pharmaceuticals for neurological conditions
- Biology, MedicineBritish journal of pharmacology
- 2009
The research suggests that small neuropeptides have advantages over growth factors in the treatment of brain injury, and that modified neuropePTides designed to overcome the limitations of their endogenous counterparts represent a novel strategy of pharmaceutical discovery for neurological disorders.
Pharmacokinetics and neurotropic effects of cyclo-L-prolylglycine and its modified analogues
- Biology, ChemistryPharmacokinetics and Pharmacodynamics
- 2022
CPG shows neuroprotective activity in ischemic-hypoxic and other brain injuries, in addition, it has a complex of other pharmacological effects and therefore CPG can be considered not only as a potential drug, but also as a basic structure for the development of new neurotropic drugs.
Design, Synthesis, and Biological Evaluation of Hybrid Glypromate Analogues Using 2-Azanorbornane as a Prolyl and Pipecolyl Surrogate.
- Biology, ChemistryACS chemical neuroscience
- 2021
Neurodegenerative disorders of the central nervous system are a class of heterogeneous pathologies affecting millions of people worldwide and represent a global health burden in developed and…
Population pharmacokinetics of NNZ‐2566 in healthy subjects
- Medicine, BiologyEuropean journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
- 2017
A Phase 1, Open-Label Study to Evaluate the Effects of Food and Evening Dosing on the Pharmacokinetics of Oral Trofinetide in Healthy Adult Subjects
- Biology, MedicineClinical Drug Investigation
- 2022
This study supports dosing of trofinetide without regard to food, suggesting a negligible food effect and lack of diurnal variation on bioavailability.
Cognitive enhancers (nootropics). Part 3: drugs interacting with targets other than receptors or enzymes. disease-modifying drugs.
- BiologyJournal of Alzheimer's disease : JAD
- 2013
The review covers the evolution of research in this field over the last 25 years and proposes assigning drugs to 19 categories according to their mechanism(s) of action.
A sustainable strategy for the assembly of Glypromate® and its structurally-related analogues by tandem sequential peptide coupling
- Biology, Chemistry
- 2020
The protocol ensures stereochemical integrity (determined by VT-NMR and rp-HPLC) and was also successfully applied for the preparation of structurally-related Glypromate® analogues with higher degree of molecular complexity compatible with functionalized amino acids with different side chains.
References
SHOWING 1-10 OF 36 REFERENCES
Neuroprotective effects of the N-terminal tripeptide of IGF-1, glycine-proline-glutamate, in the immature rat brain after hypoxic–ischemic injury
- BiologyBrain Research
- 2001
Neuroprotective effects of the N-terminal tripeptide of insulin-like growth factor-1, glycine-proline-glutamate (GPE) following intravenous infusion in hypoxic–ischemic adult rats
- Biology, MedicineNeuropharmacology
- 2004
Pharmacokinetics of glycine-proline-glutamate, the N-terminal tripeptide of insulin-like growth factor-1, in rats.
- Biology, ChemistryAnalytical biochemistry
- 2003
Central penetration and stability of N-terminal tripeptide of insulin-like growth factor-I, glycine-proline-glutamate in adult rat
- Biology, MedicineNeuropeptides
- 2005
Identification of Gly-Pro-Glu (GPE), the aminoterminal tripeptide of insulin-like growth factor 1 which is truncated in brain, as a novel neuroactive peptide.
- Biology, ChemistryBiochemical and biophysical research communications
- 1989
N-terminal tripeptide of IGF-1 (GPE) prevents the loss of TH positive neurons after 6-OHDA induced nigral lesion in rats
- BiologyBrain Research
- 2000
N-terminal tripeptide of IGF-1 improves functional deficits after 6-OHDA lesion in rats
- BiologyNeuroreport
- 2004
The study suggests that peripheral administration of GPE after onset of nigrostriatal dopamine depletion improves long-term Parkinsonian motor deficits, independent of neuronal outcome.
The IGF-I Amino-Terminal Tripeptide Glycine-Proline-Glutamate (GPE) Is Neuroprotective to Striatum in the Quinolinic Acid Lesion Animal Model of Huntington's Disease
- BiologyExperimental Neurology
- 1999
It is revealed that exogenous administration of GPE selectively prevents excitotoxin induced phenotypic degeneration of striatal projection neurons and cholinergic and NADPH diaphorase interneurons in an animal model of Huntington's disease.
Endothelin-1 induced middle cerebral artery occlusion: pathological consequences and neuroprotective effects of MK801.
- BiologyJournal of the autonomic nervous system
- 1994
Combining Insulin-Like Growth Factor Derivatives Plus Caffeinol Produces Robust Neuroprotection After Stroke in Rats
- Biology, MedicineStroke
- 2005
The GPE analogue G2MePE by itself had minimal protective effects, but when combined with caffeinol, it demonstrated robust beneficial effects on cortical and subcortical lesion size and behavioral deficit.